Through degradation of both AR and AR-V7, ITRI-148 provides durable suppression of AR signaling, underscoring AR-NTD-targeted degradation as a promising therapeutic strategy for advanced prostate cancer. This evidence concerns the gene AR and prostate carcinoma.